ANL Stock — Adlai Nortye Ltd. American Depositary Shares

Adlai Nortye Ltd. American Depositary Shares (ANL)

Updated October 16, 2026.

ANL is a Stock. Total return is -26.5% over the past 3 years, 111.6 points behind SPY at 85.1%.

Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies, with pipeline programs centered on RAS-targeting drugs and next-generation cancer immunotherapies. The company does not currently distribute to shareholders. This security appeals primarily to investors seeking exposure to early-stage oncology development with high risk and growth potential rather than income generation.

ANL performance versus SPY

Price and return data through 2026-10-16.

Total return is -26.5% over the past 3 years, 111.6 points behind SPY at 85.1%. Over the past year its total return — price change plus distributions reinvested — is 585.1%. Its deepest 1-year drawdown was 47.0%.

ANL key facts

Asset type

Stock

Asset class

Equity

Inception date

09/29/2023

Distribution frequency

None

Last close

$11.03 (as of 2026-10-16)

Market cap

$647,842,671

Average volume

336587.0

Beta

1.109

Payout ratio

0.0%

EPS

$-0.62

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 47.0%.

Who may consider ANL — and who may not

It is a weaker fit for investors who need monthly cash flow (ANL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ANL

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions